HLS Therapeutics Inc.
HLS.TOTSXHealthcare● Active
$4.40
$-0.07(-1.57%)
Market Cap$137604280
P/E Ratio—
52W High$5.765
52W Low$0.001
HLS Therapeutics Inc. (HLS.TO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · HLS.TO · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $56.47M | $56.62M | $63.07M | $61.47M | $60.01M |
| Cost of Revenue | $32.46M | $9.00M | $7.62M | $4.98M | $3.97M |
| Gross Profit | $24.01M | $47.62M | $55.45M | $56.49M | $56.04M |
| Gross Margin %(computed) | 42.52% | 84.11% | 87.91% | 91.90% | 93.38% |
| Operating Expenses | |||||
| R&D Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| G&A Expenses | $10.61M | $10.20M | $8.39M | $17.73M | $17.40M |
| Total Operating Expenses | $28.19M | $55.31M | $55.45M | $69.98M | $62.32M |
| Operating Income | ($4.18M) | ($7.69M) | ($10.35M) | ($13.44M) | ($6.24M) |
| Operating Margin %(computed) | -7.40% | -13.57% | -16.41% | -21.87% | -10.40% |
| Interest Income | $0.11M | $0.32M | $0.35M | $0.06M | $0.04M |
| Interest Expense | $7.22M | $10.08M | $8.75M | $7.32M | $6.96M |
| Income Before Tax | ($13.10M) | ($15.58M) | ($27.80M) | ($23.72M) | ($11.81M) |
| Income Tax Expense | ($0.45M) | $4.07M | ($0.27M) | ($0.12M) | $1.31M |
| Net Income | ($12.65M) | ($19.66M) | ($27.53M) | ($23.60M) | ($13.12M) |
| Net Margin %(computed) | -22.40% | -34.71% | -43.65% | -38.39% | -21.86% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.40 | $-0.62 | $-0.85 | $-0.73 | $-0.41 |
| Wtd Avg Shares | 31.53M | 31.84M | 32.26M | 32.33M | 32.18M |
| EBITDA | $18.02M | $17.22M | $12.88M | $18.00M | $25.41M |
| EBITDA Margin %(computed) | 31.91% | 30.41% | 20.43% | 29.28% | 42.35% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more HLS Therapeutics Inc. data
About HLS Therapeutics Inc. (HLS.TO) Income Statement
HLS Therapeutics Inc. (HLS.TO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, HLS.TO reported revenue of $0.06B, gross profit of $0.02B (gross margin 42.52%), and net income of ($0.01B) — a net profit margin of -22.40%.
Frequently asked questions
HLS.TO · 4 questionsHLS Therapeutics Inc. (HLS.TO) reported revenue of $0.06B for 2025, down 0.3% year-over-year.
HLS.TO revenueHLS.TO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08